QUOTE AND NEWS
FiercePharma  7 hrs ago  Comment 
About an hour and a half west of Copenhagen is a little coastal town, Kalundborg, with 16,000 inhabitants, a famous five-steepled church and a castle dating back to at least the 14th century. It also happens to be the home of the plant that...
FierceBiotech  Aug 18  Comment 
Danish financial regulators took a dim view of Novo Nordisk's decision to spend the weekend pondering the FDA's February, 2013 snub to Tresiba before spreading the news of the agency's complete response letter and the major delay that would be...
FierceBiotech  Aug 17  Comment 
The executive team here at the rapidly expanding headquarters of Novo Nordisk doesn't pull many punches. CEO Lars Rebien S ø rensen is a competitive sort who tends to be blunt, aggressive and forward-thinking; projecting a confident attitude that...
Forbes  Aug 14  Comment 
It’s not often that President Obama faces criticism from the liberal left regarding his Administration’s policy initiatives in matters involving race and disadvantage.   Which is what makes so notable an opinion piece in the latest Chronicle...
Cloud Computing  Aug 13  Comment 
Behavioral Recognition Systems, Inc. (BRS Labs), reconhecida por sua plataforma AISight® com tecnologia de ponta , a solução de análise baseada em inteligência artificial que se auto-ensina a reconhecer e alertar sobre ...
SeekingAlpha  Aug 11  Comment 
By Ulrik Lehrskov-Schmidt: The next two months are going to be very interesting for Novo Nordisk (NYSE:NVO) - a large cap pharma company with a strong position in the insulin segment. Novo Nordisk is one of those companies that just keeps doing...
Benzinga  Aug 11  Comment 
Below are the top drug manufacturers-other stocks on the NYSE in terms of dividend yield. Teva Pharmaceutical Industries (NYSE: TEVA) has a dividend yield of 2.20%. Teva Pharmaceutical's shares closed at $51.06 on Friday. Novo Nordisk A/S...
SeekingAlpha  Aug 8  Comment 
Novo Nordisk A/S (NYSE:NVO) Q2 2014 Earnings Call August 08, 2014 7:00 am ET Executives Lars Rebien Sørensen - Chief Executive Officer Kåre Schultz - President and Chief Operating Officer Mads Krogsgaard Thomsen - Chief Science...
FiercePharma  Aug 7  Comment 
Diabetes market giant Novo Nordisk surprised investors today with second-quarter earnings that came in above expectations, and the news that it plans to report critical clinical trial data on its long-acting insulin treatment, Tresiba, in...
FierceBiotech  Aug 7  Comment 
Last year's surprising FDA rejection blew a hole in Novo Nordisk's plans to capitalize on a new long-acting insulin, but the Danish drugmaker said its follow-on study is coming through ahead of schedule, clearing the way for a 2016 launch.





You may also be interested in articles related to Novo Nordisk A/S (NVO):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki